

Abstract

The present invention provides a reagent for prognostic evaluation of carcinoma patients, comprising an anti-P-LAP antibody as an active ingredient. Also, the present invention provides a method for determination of P-LAP which is a prognostic factor in carcinoma patients comprising (a) a step of contacting carcinoma tissues obtained from carcinoma patients by surgical operation with an anti-P-LAP antibody and (b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody.